---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-009044"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2023-03-22T23:59:59+00:00"
generated_at: "2026-06-17T21:31:50.825049+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology FY2022 net loss $120.7M; CFO promoted to CFO & COO

## Summary
- Net loss $120.7M ($3.65/share) vs $76.0M ($8.95) in 2021; R&D spend rose to $86.1M from $51.0M.
- Cash $180.7M with no debt as of Dec 31, 2022; runway into 1H 2025.
- Two Phase 1 trials for PYX-201 and PYX-106 initiated; preliminary data expected late 2023 to early 2024.
- CFO Pam Connealy promoted to additional role of COO effective March 22, 2023.

## SEC filing metadata
- accession: 0000950170-23-009044
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2023-03-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000095017023009044/0000950170-23-009044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000095017023009044/pyxs-20230322.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-009044
- JSON: https://secwatch.observer/filing/0000950170-23-009044.json
- Plain text: https://secwatch.observer/filing/0000950170-23-009044.txt

## Key facts
- Earnings Releases
  Pyxis Oncology, Inc. reported the full year ended December 31, 2022 results: net income $120.7 million, EPS ($3.65) per common share.
  - Period: the full year ended December 31, 2022
  - Net income: $120.7 million
  - EPS: ($3.65) per common share
  - Result: reported results
  source text: Net loss was $120.7 million, or ($3.65) per common share, for the year ended December 31, 2022, compared to $76.0 million, or ($8.95) per common share, for the year ended December 31, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782223/000095017023009044/0000950170-23-009044-index.htm
- Executive change
  Pamela Connealy changed role as Chief Financial Officer and Chief Operating Officer at Pyxis Oncology, Inc..
  - Action: promoted
  - Role: Chief Financial Officer and Chief Operating Officer
  source text: On March 22, 2023, the Company announced that Pamela Connealy, Chief Financial Officer, has been promoted to the newly created role of Chief Financial Officer and Chief Operating Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782223/000095017023009044/0000950170-23-009044-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.